Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells

Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells

Abstract Background Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients with HCC show reduced sensitivity to sorafenib during treatment. SIRT3,...

Full description

Bibliographic Details
Main Authors: Hanhee Jo, Yusun Park, Taehun Kim, Jisu Kim, Jong Sook Lee, Seon Yoo Kim, Jee-in Chung, Hae yong Ko, Jae-Chul Pyun, Kyung Sik Kim, Misu Lee, Mijin Yun
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
SIRT3
Sorafenib
Anti-tumor effect
Drug sensitivity
CDK4/6 inhibitor
Online Access:http://link.springer.com/article/10.1186/s12885-020-06822-4

Internet

http://link.springer.com/article/10.1186/s12885-020-06822-4

Similar Items